Armata Pharmaceuticals (ARMP) highlighted “positive” results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback